- Shopping Bag ( 0 items )
From The CriticsReviewer: Steven N. Hart, BS (University of Kansas Medical Center)
Description: This book is a start-to-finish approach to incorporating genomic data into the drug discovery pipeline.
Purpose: The purpose is to introduce many novel strategies, technologies, and toolboxes to aid researchers and industry professionals in progressing toward personalized medicine. More specifically, this book addresses three major components essential for personalized medicine: biomarker discovery, toxicogenomics, and pharmacogenomics with a particular emphasis on incorporating these platforms during early stages of drug design. The rationale for this approach is to stratify patient populations to identify subjects at risk of clinically significant toxicity and nonresponders to allow for safer, more effective, and more rapid drug discovery. These objectives are well defined and clearly addressed.
Audience: The book is intended to be of interest to academics, biologists in the pharmaceutical industry, and regulatory personnel who are in a position to appreciate the complexity of genomics and the wealth of useful information that it can provide. The idea is that these professionals will incorporate genomic data mining into drug discovery platforms. Many topics in this book will be of particular interest and familiarity to only one of these subgroups at a time, whereas those inexperienced in a particular area may find themselves being introduced to new concepts, but in a clear, easy to follow manner.
Features: In the book's nine chapters, readers are exposed to all relevant aspects of the strategies for and the implications of genomics in drug discovery and development. There is a strong and necessary emphasis on toxicogenomics, which serves as a major bottleneck in the drug development pipeline. Among others topics, gene expression array technology, data analysis, and how to make data publicly accessible in genomics databases - a requirement for all government funded genomics studies - are thoroughly covered.
Assessment: This book covers many of the relevant aspects of incorporating genomics into the standard drug discovery workflow. Of particular interest to me was the chapter on genomics technologies as tools in drug discovery. As an academic involved in genomics and pharmacology, I use many of the tools in this book frequently. The authors address many of the pitfalls associated with these technologies and also identify several key computational biology tools (such as databases) essential for the interpretation of genomics in drug discovery. The book also introduced me to the regulatory implications of how to transition genomics from the bench to bedside, a viewpoint that is sometimes lost in academia. Overall, it provides excellent, up-to-date coverage of the application of genomics in drug development.